A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis
Herbert Tilg(Innsbruck Medical University), Walter Reinisch(Medical University of Vienna), Harald Vogelsang(Medical University of Vienna), Herbert Lochs(Humboldt-Universität zu Berlin), Ingrid Kühn, Arthur Kaser(University of Cambridge), Geert D’Haens(Amsterdam University Medical Centers), Antoine Cortot(Centre Hospitalier Universitaire de Lille), Paul Rutgeerts(KU Leuven), Marieluise Harrer, Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Hanno Ulmer(Innsbruck Medical University), Sandrine Kruger, Othmar Ludwiczek
Cited by 91
Related Papers
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Mucosal flora in inflammatory bowel disease
|Gastroenterology|2002|1.3k
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
|Gastroenterology|1998|865
Paneth cells as a site of origin for intestinal inflammation
|Nature|2013|724